Fresh Insights

May 25, 2018

Nanotechnology in Drug Discovery and Design

This presentation takes the reader on an exciting journey, about the Science beneath the development of Oncology Nano Drug delivery systems. How the tumor mico and macro environments throws conspicuous challenges to the nanotech field? Furthermore, the presentation also gives a sneak view of Nanotherapeutics clinical landscape across development strategies and tumors.
Read More
May 14, 2018

Biosimilar Clinical Development – A Strategic Lever?

The presentation gives some key insights on the emerging biosimilars developer landscape with focus on US, EU, China, Japan, South Korea, MENA and Indian markets. Furthermore, it provides a detailed analysis on Clinical differentiation of players for major products (Bevacizumab, Trastuzumab, Adalimumab, Rituximab, Infliximab and etanercept).
Read More
February 12, 2018

Key Considerations When Developing a DOAC – Part 3

The currently approved direct oral anti-coagulants have proven to be safe and efficacious in prevention of stroke in patients with AF. However, the choice of DOAC is influenced by several factors including specific patient characteristics (renal function etc.), preference of OD versus BID, physicians comfort with the drug and the cost of drug to the patient.
Read More
December 21, 2017

Entrepreneurship Opportunities for Millennials in Pharma

Indian start-up ecosystem has been steadily growing with over 5200 start-ups in the country today. India has become the world’s...
Read More
August 10, 2017

The Wearable Story – Part 1

The rapid consumer adoption of wearable devices for the collection of health data has inspired the next revolution in clinical trial operations. The integration of wearable health monitors with smartphones has opened up several fronts in clinical research. These integrated device-app-database systems can increase the frequency and accuracy of data collection, improve operational efficiencies, and achieve greater patient engagement in the clinical trial process.
Read More
August 10, 2017

Key Considerations When Developing a DOAC – Part 2

Direct oral anticoagulants were introduced in the market to simplify the anticoagulation treatment and eventually, replace warfarin. As previously discussed, these new agents have some advantages over warfarin. One of those advantage is that all DOACs are administered in fixed doses, only adjusted for specific factors like renal functions (in some cases). Since 2008, the US and EU regulatory bodies have approved several DOACs for specific indications based on their clinical trials demonstrating non-inferiority to warfarin. The availability of DOACs have changed the way stroke prevention in AF is managed.
Read More
July 19, 2017

Key Considerations When Developing a DOAC – Part 1

In the recent years, several new classes of Cardiology drugs have emerged. Notable among them are anticoagulants that are used in several secondary indications associated with the diseases of the heart and the vasculature. In this four-part series of articles, we analyze and provide an overview of the market leading anticoagulants, indicated for stroke prevention in Atrial Fibrillation and for primary and secondary prevention of Thromboembolism.
Read More
July 18, 2017

Indian Biosimilar – Slow but Steady?

The white paper attempts to infer the biosimilar play of India-based biosimilar developers. It explores plausible scenarios for Indian developers entering the lucrative US and EU biosimilar market based on the current situation analysis of major biosimilar developers.
Read More
July 18, 2017

Biologics – A Qualitative View of The Market Opportunity

Biologics have a growing share in the pharma pipeline and increased usage as nutraceuticals. The increasing demand for biologic products has attracted huge investments in capacity and capability build-up. There remains huge opportunity for service providers/CMOs to be leveraged by providing flexibile, high-quality product delivery with customer centricity.
Read More
July 18, 2017

Oncology Biosimilar Competitive Dynamics

This paper attempts to present situation analysis of the current marketplace of Oncology biosimilars specially with respect to the industry’s micro-environment. The research and analysis herein, intends to identify positive forces and interactions that are shaping an attractive biosimilar industry in both US and EU markets.
Read More